CLINICAL TRIALS PROFILE FOR PF-04965842
✉ Email this page to a colleague
Clinical Trials for PF-04965842
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT01835197 ↗ | First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects | Completed | Pfizer | Phase 1 | This single- and multiple-ascending dose study is the first evaluation of PF-04965842, a Janus kinase1 (JAK1) inhibitor, in humans. The goal is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Western and Japanese subjects. |
| NCT02163161 ↗ | AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects | Completed | Pfizer | Phase 1 | Phase 1, open label, single dose, 3 way crossover study to evaluate the bioavailability of a solid dose formulation of PF 04965842 relative to a suspension formulation under fasting conditions and the effect of food on the bioavailability of the solid dosage formulation of PF 04965842 in healthy subjects. |
| NCT02201524 ↗ | Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis | Terminated | Pfizer | Phase 2 | Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis. The study will include three PF-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period will be 4 weeks in duration and will be followed up by a 4 week follow up period. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for PF-04965842
Condition Name
Clinical Trial Locations for PF-04965842
Trials by Country
Clinical Trial Progress for PF-04965842
Clinical Trial Phase
Clinical Trial Sponsors for PF-04965842
Sponsor Name
